lenvatinib mesylate

{
  "id": "MLC-T-ONC-004777",
  "term": "lenvatinib mesylate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat certain types of endometrial cancer, renal cell carcinoma (a type of kidney cancer), hepatocellular carcinoma (a type of liver cancer), and thyroid cancer. It is also being studied in the treatment of other types of cancer. Lenvatinib mesylate blocks certain proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Lenvatinib mesylate is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called Lenvima.",
    "A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib mesylate blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis."
  ],
  "synonyms": [
    "Lenvima",
    "E7080 mesylate",
    "multi-kinase inhibitor E7080 mesylate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lenvatinib-mesylate/"
}